Pre-Submission Review for Endocrinology Papers

Endocrinology reviewers often ask:

• is the endocrine phenotype defined precisely?
• are hormone assays, timing, thresholds, and units described clearly?
• does the design support the clinical or mechanistic claim?
• are guidelines or current practice context handled correctly?
• are subgroups, sex, age, disease stage, medication, and comorbidity accounted for?
• does the mechanism explain the endocrine finding or merely accompany it?
• is the statistical analysis proportionate to the sample and endpoints?
• does the target journal match the paper's clinical, translational, or basic-science contribution?

The paper has to show why the finding matters within endocrine medicine or hormone biology, not only that a hormone-related association exists.

In our pre-submission review work, endocrinology manuscripts most often fail when clinical endocrine claims are made from imprecise phenotype, assay, or guideline context.

Phenotype blur: the paper combines endocrine subtypes, disease stages, or treatment states that reviewers expect to be separated.

Assay context gap: hormone measurements are reported without timing, platform, reference range, medication context, or biological interpretation.

Guideline leap: the discussion implies a management change without showing why current endocrine guidance is insufficient.

Mechanism thinness: molecular or pathway language is included, but the data do not show a credible endocrine mechanism.

Diabetes boundary problem: the paper is really a diabetes-care manuscript but is framed for a broad endocrinology journal, or the reverse.

A useful review should identify whether the first objection is clinical endocrine relevance, biological mechanism, reporting, or target-journal mismatch.

JCEM describes its scope as clinical endocrinology, diabetes, and metabolism, spanning translational research from discovery science to experimental medicine and from treatment evaluation to patient-population outcomes. That scope is broad, but it is not generic. Authors need to show why the manuscript improves understanding, diagnosis, treatment, or endocrine patient outcomes.

Endocrine Society materials also emphasize official submission channels, conflicts, article types, and guideline-linked communication categories. For clinical studies, general reporting expectations such as CONSORT, STROBE, PRISMA, and EQUATOR guidance still matter.

The practical signal is that endocrine readiness is partly clinical, partly mechanistic, and partly journal-lane fit.

Send the manuscript, target journal, protocol, reporting checklist, hormone assay details, endpoint definitions, medication and treatment context, disease-stage definitions, statistical analysis plan, guideline context, data statement, figures, supplementary tables, and prior reviewer comments if available.

If the paper is clinical, include diagnostic criteria, reference ranges, treatment status, and follow-up timing. If the paper is mechanistic, include model-system validation and the link between model and endocrine question.

A useful endocrinology pre-submission review should include:

• endocrine-claim verdict
• phenotype and assay-context critique
• clinical or mechanistic relevance review
• endpoint and statistics check
• reporting-guideline check
• guideline and practice-language review
• journal-lane recommendation
• submit, revise, retarget, or diagnose deeper call

The review should not only say "add endocrine context." It should identify which endocrine context changes the reader's interpretation.

Before submission, authors often need to:

• sharpen phenotype definitions
• explain hormone assay timing and reference ranges
• separate clinical, exploratory, and mechanistic claims
• add medication, treatment, or disease-stage context
• narrow guideline or practice implications
• strengthen pathway evidence or remove unsupported mechanism language
• move diabetes-specific claims to a diabetes journal frame
• retarget from a clinical endocrine journal to a specialty, translational, metabolism, or basic-science venue

These fixes help the editor see the correct endocrine contribution quickly.

A clinical endocrine paper needs phenotype precision, endpoint discipline, and current-practice context. A translational paper needs a credible bridge between patient observations and mechanism. A basic endocrine paper needs model-system relevance, receptor or axis logic, and biological specificity. An endocrine oncology paper needs tumor biology, diagnostic or treatment relevance, and stage context. A pediatric endocrine paper needs age, growth, pubertal, developmental, and ethics context. A bone or mineral metabolism paper needs measurement methods, fracture or density relevance, and treatment context.

The AI manuscript review can flag whether the blocking risk is phenotype, assay context, guideline language, statistics, or journal fit.

Use this page when the paper's submission risk is broader endocrine logic: thyroid, adrenal, pituitary, reproductive, bone, endocrine oncology, pediatric endocrine, hormone assay, or hormone mechanism. Use diabetes research review when the manuscript depends primarily on glycemic endpoints, CGM, diabetes medication context, diabetes complications, prevention, or ADA care relevance.

That distinction keeps the page focused on the actual buyer problem.

Do not submit an endocrinology paper if the phenotype and assay context are too thin for another endocrinologist to interpret. A hormone value without timing, assay method, medication context, and disease-state framing can look less reliable than the authors intend.

Also pause if the manuscript implies a clinical management change without showing how the finding fits current practice. Endocrine journals can publish practice-relevant work, but practice language needs evidence maturity. If the design is exploratory, the discussion should say that clearly.

A final pause point is mixed endocrine scope. Manuscripts that combine thyroid, metabolic, reproductive, adrenal, or bone claims need a clear reason for grouping them. If the shared mechanism is not explicit, reviewers may see a collection of related observations rather than one endocrine argument.